While the pooled rates of arterial hypertension (28%), anorexia (19%), bleeding (8.9%), fever (15%), pruritus (16%), rash (9%) and thyroid dysfunction (7%) of any grade were similar to those reported in the IMbrave 150 trial; the rates of proteinuria (31%), fatigue (27%), ALT elevation (20%), AST elevation (35%) and perforation (2%) were higher, while the rates of diarrhea (8%) and thrombosis (9%) were lower (Fig. 3, Fig. 4). The gene discussed is GPT; the disease is Anorexia.